TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The WikiTrauma Interrupted Time Series Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* decision makers (eg, trauma program coordinators) or,~* health care professionals (eg, emergency physicians, critical care physicians, trauma surgeons, nurses, respiratory therapists, physiotherapists, or pharmacists).~* Patient representatives will be selected without any restrictions or limitations with regard to the qualifications.~* Health care professional students and trainees (eg, residents, medical students, and nursing students) will have the same access to WikiTrauma and Wiki101 as fully certified professionals.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Wiki101 and WikiTrauma (Type: EXPERIMENTAL): Wiki101, a theory-based continuing professional development (CPD) program, will train participants at the selected trauma centers to use WikiTrauma effectively and safely to create and share different types of Knowledge Transfer (KT) tools (e.g., care protocols, order sets, patient decision aids). Participants will receive Wiki101 training and then gain access to WikiTrauma with editing rights to the knowledge implementation tools (e.g. care protocols, order sets, care pathways) found in the wiki.~WikiTrauma is the wiki we created to promote best practices in trauma care and will be implemented in four trauma centers in Quebec during 12 months. During this period, we will continue to measure the impact on the quality of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nitrofurantoin and Urinary Tract Infections (UTIs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who fail a post-operative voiding trial and are willing to learn clean intermittent self-catheterization (CISC) prior to discharge from the hospital~Exclusion Criteria:~* Known drug allergy to nitrofurantoin~* A history of renal insufficiency~* Renal transplant~* Renal nephropathy~* A recent history of more than 3 Urinary Tract Infections (UTIs) per year~* Known immunocompromised condition (organ transplant, chemotherapy for cancer or arthritis, autoimmune diseases (lupus etc)).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1: Nitrofurantoin Group (Type: EXPERIMENTAL): extended release nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
- Arm 2: Placebo Group (Type: PLACEBO_COMPARATOR): identical appearing placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Transcranial Magnetic Stimulation of the Cingulate Cortex Modulate the Perception of Dyspnoea?

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Refractory dyspnoea (persisting sensation of air hunger despite optimisation of medical treatment)~2. Histocytologically proven thoracic malignancy~3. Written informed consent~Exclusion Criteria:~1. Age \<18 years~2. Left-handed~3. Structural brain disease (including cerebral metastasis)~4. Personal or family history of seizures~5. Implantable metallic objects e.g. a pacemaker, or other contraindication to transcranial magnetic stimulation~6. Pregnant or breast feeding~7. Previous electroconvulsive therapy (ECT)~8. Poor mobility~9. Visual impairment~10. Lack of social support / home to go to after the study treatment~11. Alcohol dependency~12. PaCO2 \>6kPa at rest~13. Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services.~Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Localized intermediate-risk or high-risk prostate cancer cT3~* Gleason score ≥ 7 (3+4 and/or 4+3) and/or~* PSA ≥ 20 ng/ml~* intact preoperative erectile function with an IIEF ≥ 21 (IIEF-6).~Exclusion Criteria:~* IIEF \< 21~* Operations in the past 6 months which could limit the erectile function~* Erectile dysfunction in the history or current medication for erectile dysfunction~* Current involvement in another comparable study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: SHAM_COMPARATOR): Radical prostatectomy without implantation of allograft
- Treatment group (Type: EXPERIMENTAL): Radical prostatectomy with implantation of allograft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. American Society of Anesthesiologists score between 1-3~2. Scheduled to undergo Anterior Cruciate Ligament reconstruction with patellar tendon graft or allograft under general anesthesia~Exclusion Criteria:~1. Localized infection of the groin or generalized sepsis.~2. Hypersensitivity or known allergy to local anesthetics.~3. Preexisting nerve damage in surgical limb.~4. History of chronic pain with either (a) daily opioid requirement exceeding the equivalent of 50 mg morphine or (b) daily prescription of tricyclic antidepressants, gabapentin, pregabalin, or tramadol for pain.~5. Patients who elect to have knee surgery under spinal anesthesia or who cannot undergo general anesthetic.~6. Patients who decline to have a femoral nerve block with catheter.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bupivacaine (Type: ACTIVE_COMPARATOR): All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine)through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
- Placebo (Type: PLACEBO_COMPARATOR): All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine) through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with saline solution, and the infusion will be started at 6 ml/hr. gh the catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ultrasonographic evidence of premature dilatation of the internal os~* Prolapse of the chorio-amniotic membranes into the endocervical canal~* Functional cervical length less than 25mm~* Exacerbation of these ultrasound findings with transfundal and/or suprapubic pressure~Exclusion Criteria:~* Any fetal chromosomal or structural anomaly~* Multiple gestation~* Known allergy to progesterone~* Ruptured membranes~* Vaginal bleeding~* Intra-amniotic infection (diagnosed clinically or by amniocentesis)~* Prolapse of endocervical membranes beyond the external cervical os~* Persistent uterine activity accompanied by cervical change~* Obstetrically indicated delivery.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): McDonald cerclage
- 2 (Type: ACTIVE_COMPARATOR): 17 hydroxyprogesterone caproate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All patients with Retinal Vein Occlusion (RVO) with available initial imaging and documented treatment failure with bevacizumab, ranibizumab, or aflibercept. Treatment failure is defined as lack of anatomic improvement (persistent intraretinal cystic changes/macular edema with central subfield thickness greater than 250 microns on time-domain OCT or greater than 275 microns on spectral domain OCT) with lack of visual improvement (less than 2 lines of visual gain by Snellen acuity), despite 3 to 6 intravitreal anti-VEGF treatments over the preceding 6 months.~Exclusion Criteria:~* Co-existing or pre-existing macular degeneration, diabetic macular edema, or other confounding disease processes~* Interval surgical intervention, such as cataract surgery, that may confound visual outcomes.~* Pregnancy~* Coexisting conditions that would represent relative or absolute contraindications usage of ozurdex implant, including:~* Ocular or periocular infections (including viral disease of the cornea and conjunctiva such as active epithelial herpes simplex keratitis, vaccinia, varicella, mycobacterial infection, and fungal diseases)~* Advanced glaucoma~* Aphakic eyes with rupture or missing posterior lens capsule~* Eyes with anterior chamber intraocular lens and missing posterior lens capsule~* Patients with known hypersensitivity to components of this product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ozurdex implant (Type: OTHER): Intravitreal injection of Ozurdex implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Impact of Different Compression of the Hand Versus Free Hand on the Implementation of the Precision Grip

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria :~* Patient admitted from Leon Bérard Hospital~* Burn hand with 2nd or 3nd degree depp~* Dominant hand if bilateral's burning~* Patients requiring compression of the hand~* Patient receiving final compression gloves since seven days ± two days weekend~* Patient affiliated to a social security~Exclusion Criteria :~* No burning of the hand~* contraindication for the use of compression~* Incompatible articular balance with achievement tests~* Patients already included in a second study~* Minor patient or pregnant woman~* Presence of cognitive disorder, preventing the achievement of tests~* Guardianship or individual under the protection of a conservator~* Patients not receiving social security

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing Irrisept to Saline Irrigation for Infection Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult, 18 or over~2. Gustilo-Anderson type III open tibia fracture~3. Able to obtain informed consent from patient~Exclusion Criteria:~1. Minor, under 18~2. Pregnancy~3. Prisoner~4. Allergic to chlorhexidine gluconate~5. Allergic to vancomycin or tobramycin~6. Patient's tibia is unable to accommodate the smallest antibiotic nail~7. Unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard operative debridement and spanning external fixator (reference/control group) (Type: ACTIVE_COMPARATOR): This is the standard of care management. Patient will go to the operating room (OR) first for irrigation and debridement with normal saline and external fixation. Will return to OR at a later date for definitive fixation.
- Spanning external fixator with Irrisept irrigation (treatment group 1) (Type: EXPERIMENTAL): Patient will go to the operating room (OR) first for irrigation and debridement with Irrisept (the experimental irrigation solution) and external fixation. Will return to OR at a later date for definitive fixation.
- Antibiotic-coated medullary nail with saline irrigation (treatment group 2) (Type: EXPERIMENTAL): Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with normal saline.
- Antibiotic-coated medullary nail with Irrisept irrigation (treatment group 3) (Type: EXPERIMENTAL): Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with Irrisept (the experimental irrigation solution).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Pain Protocol Limiting Narcotics for Laparoscopic Hand-assisted Donor Nephrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all individuals undergoing laparoscopic donor nephrectomies at Stony Brook Hospital~Exclusion Criteria:~* Patients excluded as a potential kidney donor or surgical candidate (renal failure, cancer, uncontrolled hypertension or diabetes, cognitively impaired adults, children, history of stroke, complicated coronary history or pregnant)~* Patients with a history of chronic pain or chronic pain medication use~* Patients who are undergoing open nephrectomies~* Allergy to NSAID or acetaminophen~* Hepatic disease or elevated transaminases~* Peptic Ulcer Disease~* Probenecid use~* History of traumatic brain injury~* Contraindications of Ketamine Use (recent head trauma, open eye injury or glaucoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Patients in this group will receive ketamine, morphine PCA and caldolor for pain control
- placebo (Type: PLACEBO_COMPARATOR): Patients in this group receive placebo, morphine PCA, and caldolor for pain control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All pediatric febrile neutropenia patients treated on outpatient basis~* Age 3 years - 18 years~* Fulfilling low risk criteria ( Hematological malignancies in remission, No identifiable focus of infection, No Pneumonia/ mucositis / GI sepsis / Nausea-vomiting/ neurologic-mental status changes/ Central Venous Catheter (CVC) related infection, Anticipated Absolute Neutrophil Count (ANC) recovery ≤ 10 days, No organ dysfunction, Hemodynamically stable, Culture negative )~* Afebrile for at least 24 hours, on intra-venous antibiotics~Exclusion Criteria:~* Bone marrow involvement in solid tumor~* Already enrolled once, in previous episode~* On antibiotics prophylaxis~* Retroviral positive patients~* Patient undergone stem cell transplant

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- arm (A) - stoppage of antibiotics (Type: EXPERIMENTAL): patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
- arm (B) - oral antibiotics till ANC ≥ 500 (Type: ACTIVE_COMPARATOR): patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity Endometrial Development in Assisted Reproduction.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~* Less than 5mm despite 10 days with standard doses of estrogen therapy (6mg / 24h) Endometrio~Exclusion Criteria:~* History of pelvic inflammatory disease~* Risk of infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Endometrium with less than 5mm (Type: EXPERIMENTAL): Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~Less than 5mm despite 10 days with standard doses of estrogen
- Endometrium with more than 5mm (Type: NO_INTERVENTION): Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~More than 5mm despite 10 days with standard doses of estrogen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age (GA) between 34\^0/7 and 35\^6/7 weeks.~* Subjects with symptoms of preterm labour.~* Subjects with a singleton pregnancy.~Exclusion Criteria:~* Foetal death in utero in current pregnancy or in previous pregnancy after gestational week 24 or expected high risk of foetal death in the current pregnancy.~* Any contraindications for the mother or the foetus to stop labour or prolong pregnancy or any maternal or foetal conditions likely to indicate iatrogenic delivery.~* Use of cervical cerclage or a pessary in situ in the current pregnancy.~* The Subject has any condition which in the opinion of the PI constitutes a risk or a contraindication for the participation of the subject in the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OBE001 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Skin-to-skin Contact on Interaction and Parents' Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parents staying at the NICU with a single preterm infant born \<33 weeks of gestation~* The family should have been transferred to family-room from intensive care~* Swedish speaking parents~Exclusion Criteria:~* Infants with major congenital malformation,~* Infants with intraventricular hemorrhage grade III-IV~* Infants with chromosome defect that could affect the infant´s ability to interact.~* Parents with sleeping disorder~* Parents with psychiatric problem or drug use.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous skin-to-skin contact (Type: EXPERIMENTAL): Infants assigned to SSC will rest skin-to-skin on parents' chest 24 hours a day for four days alternating between the parents.
- Standard Care (Type: ACTIVE_COMPARATOR): Infants and parents will receive standard care provided in the NICU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues